Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

NCT ID: NCT00566501

Last Updated: 2021-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 915 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-14
• Study Completion Date: 2010-04-01

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.

Conditions

Alzheimer's Disease

Keywords

Moderate-to-severe; Alzheimer's; Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)

Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

Donepezil SR 23 mg once daily orally.

Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)

Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

Donepezil SR 23 mg once daily orally.

Interventions

Donepezil

Donepezil SR 23 mg once daily orally.

Intervention Type: DRUG

Other Intervention Names

Aricept

Eligibility Criteria

Inclusion Criteria

1. Written informed consent from the participant (if possible) or from the participant's legal guardian or other representative at the time of the Baseline visit, prior to beginning any assessments or activities.

2. Completion of study E2020-G000-326 (NCT00478205) without ongoing SAEs or history of serious adverse drug reactions during study E2020-G000-326 (NCT00478205).

3. Participant must enroll in the present study within 3 days of completion of study E2020-G000-326 (NCT00478205).

4. Health: physically healthy and ambulatory or ambulatory-aided (that is, walker or cane); corrected vision and hearing sufficient for compliance with testing procedures.

5. Co-morbid medical conditions must be well-controlled as determined by the investigator.

6. Participants undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) may be included, provided that doses are within the approved dose range as specified in the Physician's Desk Reference or local equivalent

7. Concomitant Medications: Participants undergoing treatment with the following medications may be enrolled in the study provided the following conditions are met: chronic daily benzodiazepine use if doses are stable within an approved dose range; bronchodilator medications for treatment of chronic obstructive pulmonary disease (COPD) as long as drug is administered via metered dose inhaler within approved dose range; memantine if taken at doses of 20 mg/day or less, provided that the dose is stable.

8. The participants must have a relative/caregiver who supervises the regular taking of the drug at the correct dose and is alert for possible side effects, unless the participant's legal guardian takes on this task.

2. Participants with any active or clinically-significant conditions affecting absorption, distribution, or metabolism of the study medication (example, inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance).

3. Known plan for elective surgery during the study period that would require general anesthesia and administration of neuromuscular blocking agents, such as succinylcholine, to induce paralysis/muscle relaxation. Minor surgery, such as colonoscopy or cataract surgery, will be permitted as long as it does not require the use of these paralytic agents.

4. Participants who are unwilling or unable to fulfill the requirements of the study.

5. Use of any prohibited prior or concomitant medications.

6. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study.

7. Participant taking concomitant antidepressant medication known to have significant anticholinergic effects, such as tricyclic antidepressants prescribed at doses recommended for the treatment of major depression.

8. Participants who cannot swallow or who have difficulty swallowing whole tablets.

9. Participants taking any alternative medication such as vitamins and/or herbal products or alternative medical techniques such as acupuncture or acupressure specifically for the treatment of Alzheimer's disease.

Exclusion Criteria

1. Caregivers who are unwilling or unable to give informed consent or otherwise to fulfill the requirements of the study.

2. Any condition that would make the caregiver, in the opinion of the investigator, unsuitable for the study.

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 91 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Limited

INDUSTRY

Sponsor Role: collaborator

Eisai Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jane Yardley, Ph.D

Role: STUDY_DIRECTOR

Eisai Limited

Locations

Apex Research Institute

Santa Ana, California, United States

Countries

United States

Other Identifiers

2006-004890-93

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

E2020-G000-328

Identifier Type: -

Identifier Source: org_study_id